Is PT-141 (Bremelanotide) Safe in the First Trimester?

The Bottom Line on Bremelanotide and Pregnancy

PT-141 (bremelanotide) is contraindicated throughout pregnancy. The FDA-approved prescribing information for Vyleesi states plainly that the drug should be discontinued as soon as pregnancy is recognized. This is not a theoretical precaution. Animal reproductive toxicity studies show that bremelanotide caused fetal loss, reduced fetal body weight, and skeletal variations at exposures at or below the human therapeutic dose.

Because bremelanotide is approved only for premenopausal women, the population most likely to use it overlaps directly with women who are either planning a pregnancy, actively trying to conceive, or not yet aware they have conceived. That overlap makes the pregnancy safety question one every prescribing clinician and every woman considering PT-141 should address before the first dose.

The drug has a short half-life of approximately 2.7 hours, so systemic exposure clears relatively quickly after a single subcutaneous dose. But even brief first-trimester exposure during organogenesis, the period from roughly week 3 through week 10 when fetal organs form, carries theoretical risk based on the preclinical findings.

What "Contraindicated in Pregnancy" Actually Means

The word "contraindicated" in an FDA label means the drug should not be used in that population because the risks clearly outweigh any potential benefit. It is the strongest safety designation the label can carry. For bremelanotide, the FDA label places it in the category of drugs with demonstrated animal risk and no reassuring human data, previously described under the old letter system as roughly equivalent to a Category D or X designation for pregnancy, depending on the specific risk-benefit framing.

Who Is Most at Risk of Accidental Exposure

Women in their late reproductive years or perimenopause transition are the FDA-approved target group for bremelanotide. Perimenopause brings irregular cycles and fluctuating fertility, which can make it genuinely difficult to know whether a missed period signals pregnancy or anovulation. If you are using bremelanotide and your cycle changes in a way that could indicate pregnancy, take a home pregnancy test promptly and contact your provider.

Pregnancy and Lactation Safety: Full Detail

This section is required under WomanRx editorial standards for every drug article. What follows covers the animal data, the complete absence of human pregnancy data, lactation transfer, and the contraception requirement.

Animal Reproductive Toxicity Data

The Vyleesi prescribing information reports that in rat studies, subcutaneous administration of bremelanotide during organogenesis at doses producing exposures approximately equal to the recommended human dose (1.75 mg) resulted in increased post-implantation loss, reduced fetal body weights, and increased skeletal variations. At higher doses, the effects were more pronounced. These findings occurred in the absence of significant maternal toxicity, which is a red flag because it suggests the embryo and fetus are specifically sensitive to the drug, not simply responding to a sick mother.

Rabbit studies showed similar patterns of embryo-fetal toxicity. Across species, the data consistently point to a drug that disrupts normal early fetal development. Melanocortin receptors, the target system for bremelanotide, are expressed in placental and fetal tissue, providing a plausible biological mechanism for these findings.

Human Pregnancy Data

There are no adequate, well-controlled studies of bremelanotide in pregnant women. Full stop. The drug received FDA approval in 2019, and as of the most recent label update, zero human pregnancy outcome data have been published in peer-reviewed form. Any claim that PT-141 is "probably fine" in early pregnancy is extrapolation without evidence. ACOG guidance on medication use in pregnancy consistently emphasizes that the absence of human data does not mean safety, particularly when animal data are concerning.

Women have been historically underrepresented in drug trials, and drugs approved for use in reproductive-age women often reach the market with minimal or no pregnancy safety data. Bremelanotide is a clear example. The honest answer is: we do not know what bremelanotide does to a first-trimester human fetus. What we do know is that it harms rat and rabbit fetuses at exposures that match or fall below the doses women receive.

Lactation and Breastfeeding

LactMed, the NIH database of drugs and lactation, notes that no published data exist on whether bremelanotide is excreted into human breast milk, its effect on milk production, or its effect on a breastfed infant. Given the drug's mechanism of action at melanocortin receptors and its peptide structure, the theoretical potential for transfer into milk and effects on the nursing infant cannot be ruled out.

The FDA label advises that breastfeeding is not recommended during bremelanotide treatment. Postpartum women experiencing hypoactive sexual desire, which is extraordinarily common in the first year after delivery due to prolactin elevation, sleep deprivation, and estrogen withdrawal, should discuss non-pharmacologic options and any medication choices with their provider before starting bremelanotide while nursing.

Contraception Requirement

Because bremelanotide is contraindicated in pregnancy and is approved specifically for premenopausal women who may have active fertility, the FDA label recommends using reliable contraception throughout treatment. The following framework summarizes the contraception discussion every woman should have with her prescriber before starting bremelanotide:

| Life Stage | Pregnancy Risk | Contraception Recommendation | |---|---|---| | Reproductive years, not TTC | Active | Use reliable method (IUD, implant, combined hormonal contraceptive, or barrier plus spermicide) throughout treatment | | Trying to conceive | High overlap | Bremelanotide is not appropriate; address HSDD via non-pharmacologic routes | | Perimenopause, still menstruating | Variable | Assume fertility possible; use contraception unless confirmed infertile (12+ months amenorrhea) | | Post-menopause | None | Bremelanotide not FDA-approved for this life stage; off-label use carries same lactation/fetal caveats if any residual risk is relevant | | Postpartum, not breastfeeding | Returning quickly | Ovulation can precede first postpartum period; use contraception | | Postpartum, breastfeeding | Reduced but not zero | Bremelanotide not recommended during lactation regardless of pregnancy risk |

What to Do If You Took PT-141 Before Knowing You Were Pregnant

This is a clinical scenario that happens. A woman uses bremelanotide, discovers two or three weeks later that she was already pregnant at the time of the dose, and needs to know what her actual risk is and what steps to take.

Step 1: Stop the Drug Immediately

Do not take another dose. The FDA label is clear: discontinue bremelanotide as soon as pregnancy is recognized.

Step 2: Document the Exposure

Write down the date(s) you took bremelanotide, the dose (standard is 1.75 mg subcutaneous), and approximately when you believe conception occurred. This timeline matters for your clinician to estimate whether the exposure fell before the embryonic period (before week 3, when implantation is not yet complete) or during early organogenesis (weeks 3 through 8), when risk is theoretically highest.

Step 3: Contact Your OB-GYN or Maternal-Fetal Medicine Specialist

A maternal-fetal medicine (MFM) specialist can review the preclinical data in the context of your specific exposure timing and discuss whether additional monitoring such as early anatomy ultrasound is warranted. ACOG recommends that any medication exposure in the first trimester be documented and assessed for teratogenic risk through consultation.

Step 4: Report to the FDA and the Manufacturer's Pregnancy Registry

If no registry exists at the time of your exposure (none was listed in the 2019 Vyleesi label), report the exposure to FDA MedWatch. Population-level data on accidental first-trimester exposures help build the human safety database that currently does not exist.

What the Risk Is and Is Not

Accidental single-dose exposure before a known pregnancy does not guarantee fetal harm. The animal data established risk at specific dose levels and timings. A single 1.75 mg dose taken once before a positive pregnancy test is a different exposure profile from repeated doses during active organogenesis. No clinician can promise you that a single prior dose caused no harm, but no one can confirm it did either. The honest clinical position is: the risk from a single accidental pre-recognition exposure is unknown, likely lower than the animal studies' repeated-dose protocols suggest, and warrants monitoring rather than panic.

How Bremelanotide Works and Why Pregnancy Timing Matters

Bremelanotide is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts as a nonselective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. In the context of sexual desire, MC4R activation in the central nervous system is thought to be the primary driver of its pro-desire effect.

The clinical trials that supported FDA approval, the RECONNECT trials published in JAMA (Simon et al., 2019), enrolled premenopausal women with generalized acquired HSDD and showed that bremelanotide increased the number of satisfying sexual events by approximately 0.5 per month compared to placebo, and reduced distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The trials enrolled 1,247 women across two randomized, placebo-controlled studies. Pregnancy was an exclusion criterion in both.

Melanocortin receptors are not restricted to the central nervous system. MC1R is expressed in placental trophoblasts, and MC2R, MC3R, and MC4R have been detected in fetal adrenal and neural tissue. Agonism at these receptors during organogenesis could theoretically interfere with normal trophoblast invasion, placental vascularization, or fetal adrenal development. This is the mechanistic basis for the reproductive concern, even though direct human evidence is absent.

Who Bremelanotide Is Right For and Not Right For, by Life Stage

Right For

Bremelanotide is FDA-approved for premenopausal women with generalized acquired HSDD. This means women who:

• Had satisfactory sexual desire at some point and have lost it without a clear, reversible cause
• Are not pregnant, not breastfeeding, not trying to conceive
• Have ruled out or are managing contributing factors such as hypothyroidism, uncontrolled depression, relationship distress, or medication side effects (SSRI-induced sexual dysfunction being one of the most common)
• Do not have uncontrolled hypertension (bremelanotide transiently raises blood pressure by approximately 2 to 4 mmHg after each dose; the FDA label warns against use in women with cardiovascular disease)

Not Right For

• Pregnant women at any trimester
• Women trying to conceive who are not using reliable contraception
• Breastfeeding women
• Postmenopausal women (off-label; no efficacy or safety data in this group)
• Women with PCOS whose low desire is driven primarily by androgen excess or insulin resistance (treating the underlying PCOS with lifestyle, metformin, or inositol supplementation addresses desire more directly than a central melanocortin agonist would)
• Women whose low desire is situational (stress, relationship conflict, sleep deprivation) rather than generalized and acquired

PCOS-Specific Note

PCOS affects roughly 8 to 13 percent of reproductive-age women globally and is one of the leading causes of anovulatory infertility. Many women with PCOS report reduced sexual satisfaction and desire, often intertwined with body image concerns, hyperandrogenism, and depression. Bremelanotide is not studied in this population. Women with PCOS who want pharmacologic support for HSDD should work with a reproductive endocrinologist to treat the underlying hormonal picture first, before considering a central-acting agent during a period of active fertility management.

Perimenopause-Specific Note

Bremelanotide carries no FDA approval for postmenopausal or perimenopausal women. The RECONNECT trials enrolled premenopausal women only. Perimenopausal women experiencing low desire more often benefit from addressing estrogen and testosterone decline directly, and The Menopause Society recommends hormone therapy and, where indicated, compounded testosterone as first-line pharmacologic options for desire disorders in the menopause transition. The use of bremelanotide in perimenopause is off-label and lacks clinical trial data in this group.

Alternatives to Bremelanotide During Pregnancy and the Trying-to-Conceive Window

Low sexual desire during pregnancy is common and is not a medical emergency requiring pharmacologic treatment. Physiologic shifts in estrogen, progesterone, human chorionic gonadotropin, fatigue, nausea, and body image changes all contribute. A few evidence-supported approaches are appropriate regardless of trimester:

• Mindfulness-based cognitive therapy for sexual dysfunction. A 2019 randomized trial by Paterson et al. showed mindfulness training improved sexual desire and reduced distress in women with sexual interest/arousal disorder.
• Couples therapy and communication-focused sex therapy. Effective, free of fetal risk, and address the relational component that pharmacotherapy cannot.
• Treating underlying conditions. Iron-deficiency anemia in pregnancy, gestational hypothyroidism, and untreated perinatal depression all suppress libido. Treating the cause is more effective than masking the symptom.
• Flibanserin (Addyi). The other FDA-approved HSDD drug is also contraindicated in pregnancy and is incompatible with alcohol. It carries its own separate reproductive safety concerns. It is not a safer alternative during pregnancy.

For women in the trying-to-conceive window who have stopped bremelanotide, none of the evidence suggests a required washout period before conception attempts beyond allowing the drug's 2.7-hour half-life to clear. However, discussing timing with your prescriber is wise given the absence of human fertility data.

The Evidence Gap: What We Still Do Not Know

Women deserve a direct answer about what is known versus extrapolated. Here is where the evidence stands as of early 2025:

• Animal data: consistent signal of embryotoxicity across rats and rabbits at or below human therapeutic doses. This is the strongest evidence for the contraindication.
• Human pregnancy data: zero published cases or cohort data from controlled studies. Any human pregnancy outcome data come from accidental exposures that may never have been reported or published.
• Lactation transfer in humans: not measured. Theoretical risk cannot be excluded.
• Fertility effects: the preclinical studies showed post-implantation loss, which raises a theoretical question about whether bremelanotide could impair implantation if taken in the luteal phase of a conception cycle. No human data address this question.
• Paternal exposure: no studies have examined whether male partner use of PT-141 (in off-label ED contexts) affects sperm or embryo. This is not directly relevant to this article but is an open question.

ACOG Committee Opinion 718 and general ACOG guidance on medication safety in pregnancy consistently acknowledge that limited data should be interpreted conservatively when animal reproductive signals exist.